Phillip Cunnah

Title: The Innovations of Phillip Cunnah

Introduction

Phillip Cunnah is a notable inventor based in Porto Salvo, Portugal. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents. His work focuses on innovative solutions for midkine-related disorders.

Latest Patents

Cunnah holds a patent for a Midkine antibody. This patent is directed to isolated or recombinant proteins, such as antibodies, which bind to and inhibit or reduce the function of midkine (MK). These proteins are intended for use as therapeutic and diagnostic agents for midkine-related disorders. The patent also includes nucleic acid sequences that encode these proteins and their expression in recombinant host cells. Notably, the disclosure emphasizes humanized antibodies derived from murine antibody IP14, which specifically bind to human MK.

Career Highlights

Phillip Cunnah is associated with Cellmid Limited, a company that focuses on developing innovative therapeutic solutions. His work at Cellmid Limited has positioned him as a key player in the biotechnology sector. Cunnah's expertise in antibody development has contributed to advancements in medical treatments.

Collaborations

Cunnah collaborates with talented professionals in his field, including Maria Halasz and Darren Jones. These collaborations enhance the research and development efforts at Cellmid Limited, fostering innovation and progress in therapeutic applications.

Conclusion

Phillip Cunnah's contributions to biotechnology, particularly through his patent on Midkine antibodies, highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of midkine-related disorders.